Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics
Roche has secured its third antibody-drug conjugate deal of the year, this time agreeing to hand $36 million in upfront payments to Oxford BioTherapeutics.
Roche has secured its third antibody-drug conjugate deal of the year, this time agreeing to hand $36 million in upfront payments to Oxford BioTherapeutics.
